Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna C Renner

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
ACS Medicinal Chemistry Letters|November 19, 2025
Broadening Degrader Therapeutics: Keap1 PROTACs, Antimalarial Hybrids, and PLK1 Inhibition of NLRP3 InflammasomesAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|February 18, 2026
From Solid-State Control to Predictive Precision: Building a Deployable Ecosystem for Psychedelic TherapeuticsAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|December 17, 2025
Dual-State KRAS G12C Inhibitors as Emerging Therapeutics for Brain and Lung MetastasesAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|May 20, 2026
Targeted Modulation of YAP Signaling: Advancing Small-Molecule Strategies in Oncology and Tissue RegenerationAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|June 17, 2026
Degrading Immune Checkpoints and Coordinating Oncogenic Signaling: Emerging Strategies in Cancer TherapyAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|June 17, 2026
Targeted Protein Degradation and Metabolic Inhibition as Complementary Therapeutic Strategies: TEAD PROTACs and NAT8L Inhibitors in OncologyAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|June 17, 2026
Degradation and Detection: Integrating BCL6 Targeted Protein Degradation with Biomarker-Guided BET Inhibition in CancerAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|May 20, 2026
Advancing KRAS Modulation: Expanding Chemical Space toward Broad-Spectrum RAS-Driven OncologyAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|May 20, 2026
Selective Induction of Estrogen Receptor-Dependent Stress Signaling as a Therapeutic Strategy in Resistant Breast CancerAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|May 20, 2026
Acyclic Glutarimide PROTAC Precursors Enable Controlled Protein Degradation and Expand Cereblon Ligand SpaceAnna C Renner, Robert B Kargbo
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
ACS Medicinal Chemistry Letters|November 19, 2025
Broadening Degrader Therapeutics: Keap1 PROTACs, Antimalarial Hybrids, and PLK1 Inhibition of NLRP3 InflammasomesAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|February 18, 2026
From Solid-State Control to Predictive Precision: Building a Deployable Ecosystem for Psychedelic TherapeuticsAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|December 17, 2025
Dual-State KRAS G12C Inhibitors as Emerging Therapeutics for Brain and Lung MetastasesAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|May 20, 2026
Targeted Modulation of YAP Signaling: Advancing Small-Molecule Strategies in Oncology and Tissue RegenerationAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|June 17, 2026
Degrading Immune Checkpoints and Coordinating Oncogenic Signaling: Emerging Strategies in Cancer TherapyAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|June 17, 2026
Targeted Protein Degradation and Metabolic Inhibition as Complementary Therapeutic Strategies: TEAD PROTACs and NAT8L Inhibitors in OncologyAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|June 17, 2026
Degradation and Detection: Integrating BCL6 Targeted Protein Degradation with Biomarker-Guided BET Inhibition in CancerAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|May 20, 2026
Advancing KRAS Modulation: Expanding Chemical Space toward Broad-Spectrum RAS-Driven OncologyAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|May 20, 2026
Selective Induction of Estrogen Receptor-Dependent Stress Signaling as a Therapeutic Strategy in Resistant Breast CancerAnna C Renner, Robert B Kargbo
ACS Medicinal Chemistry Letters|May 20, 2026
Acyclic Glutarimide PROTAC Precursors Enable Controlled Protein Degradation and Expand Cereblon Ligand SpaceAnna C Renner, Robert B Kargbo
Pageof 4